We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
-19.33%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$335M
AUM Growth
-$24.9M
Cap. Flow
+$60.4M
Cap. Flow %
18.05%
Top 10 Hldgs %
58.78%
Holding
55
New
11
Increased
22
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
ZBH icon
Zimmer Biomet
ZBH
+$17.8M
2
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$11.9M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$11.5M
4
ACCD
Accolade Inc
ACCD
+$11.3M
5
ADCT icon
ADC Therapeutics
ADCT
+$10M

Top Sells

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$12.3M
2
GH icon
Guardant Health
GH
+$9.7M
3
KURA icon
Kura Oncology
KURA
+$6.79M
4
KIDS icon
OrthoPediatrics
KIDS
+$6.68M
5
PFE icon
Pfizer
PFE
+$5.97M

Sector Composition

Rank Sector Weight
1 Healthcare 95.26%
2 Industrials 4.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$33.5M 10%
1,349,980
+418,468
+45% +$11.9M
ADCT icon
2
ADC Therapeutics
ADCT
$146M
$30.2M 9.04%
9,570,000
+2,519,700
+36% +$10M
ROIV icon
3
Roivant Sciences
ROIV
$25.2B
$21.1M 6.32%
2,000,000
+140,000
+8% +$1.53M
BBIO icon
4
BridgeBio Pharma
BBIO
$16.5B
$20.3M 6.06%
800,000
+210,470
+36% +$5.75M
ZBH icon
5
Zimmer Biomet
ZBH
$17.7B
$18.5M 5.51%
170,000
+151,092
+799% +$17.8M
MGTX icon
6
MeiraGTx Holdings
MGTX
$1.09B
$18.3M 5.48%
4,352,700
+335,399
+8% +$1.69M
STTK icon
7
Shattuck Labs
STTK
$710M
$18M 5.39%
4,670,000
+945,000
+25% +$7.68M
KURA icon
8
Kura Oncology
KURA
$922M
$13M 3.88%
629,900
-330,100
-34% -$6.79M
CYTK icon
9
Cytokinetics
CYTK
$11B
$12.5M 3.72%
230,000
-15,000
-6% -$905K
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.84B
$11.3M 3.38%
+551,544
New +$11.5M
MIRM icon
11
Mirum Pharmaceuticals
MIRM
$6.89B
$10.8M 3.22%
314,800
-150,200
-32% -$3.94M
KELYA icon
12
Kelly Services Class A
KELYA
$526M
$10.5M 3.15%
492,340
+143,654
+41% +$3.26M
ZYME icon
13
Zymeworks
ZYME
$1.68B
$10M 3%
1,180,000
+769,052
+187% +$6.85M
IMVT icon
14
Immunovant
IMVT
$8.09B
$8.58M 2.56%
325,000
+130,000
+67% +$3.7M
SDGR icon
15
Schrodinger
SDGR
$1.12B
$7.14M 2.13%
+369,261
New +$8.51M
ABCL icon
16
AbCellera Biologics
ABCL
$1.62B
$6.96M 2.08%
2,352,633
+562,633
+31% +$2.13M
ALKS icon
17
Alkermes
ALKS
$8.82B
$6.63M 1.98%
275,000
+60,000
+28% +$1.47M
ERAS icon
18
Erasca
ERAS
$6.63B
$6.49M 1.94%
2,750,000
-909,755
-25% -$1.96M
VKTX icon
19
Viking Therapeutics
VKTX
$4.04B
$6.1M 1.82%
115,000
+75,954
+195% +$4.98M
PRTA icon
20
Prothena Corp
PRTA
$458M
$5.92M 1.77%
286,926
+116,457
+68% +$2.52M
KIDS icon
21
OrthoPediatrics
KIDS
$485M
$5.76M 1.72%
200,216
-218,045
-52% -$6.68M
OPCH icon
22
Option Care Health
OPCH
$3.4B
$5.68M 1.7%
205,000
+105,000
+105% +$3.13M
DXCM icon
23
DexCom
DXCM
$27.6B
$5.59M 1.67%
49,317
+26,317
+114% +$3.33M
ACCD
24
DELISTED
Accolade Inc
ACCD
$5.33M 1.59%
+1,489,525
New +$11.3M
COGT icon
25
Cogent Biosciences
COGT
$6.79B
$4.21M 1.26%
500,000
-55,500
-10% -$421K
1
2 3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q2 2024 Portfolio in Review

As of Q2 2024, Prosight Management held 55 positions worth $335M, down 6.9% from $359M the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Prosight Management deployed $60.4M of net new capital in Q2 2024, opening 11 new positions and adding to 22 existing holdings. Its largest new stake was Syndax Pharmaceuticals: 551,544 shares worth $11.3M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 97% a quarter earlier, followed by Industrials.

On the sell side, the largest reduction was Medtronic, an estimated $12.3M trimmed.

  • Prosight Management's largest Q2 2024 buy was Syndax Pharmaceuticals: 551,544 shares worth $11.3M.
  • Prosight Management added most to Zimmer Biomet in Q2 2024, an estimated $17.8M increase.
  • Prosight Management's biggest Q2 2024 reduction was Medtronic, cutting an estimated $12.3M.
  • Prosight Management fully exited Guardant Health in Q2 2024, selling an estimated $9.7M.
  • Prosight Management's ten largest holdings make up 59% of its $335M portfolio in Q2 2024.
  • Prosight Management opened 11 new positions and closed 9 in Q2 2024.
  • Prosight Management's portfolio value fell 6.9% quarter-over-quarter to $335M.

Based on Prosight Management's 13F filing for Q2 2024, filed 14 Aug 2024.